glioma/nauzea

Odkaz sa uloží do schránky

Vyberte typ zoradenia

Strana 1 od 215 výsledky

A Phase II single-arm trial of palonosetron for the prevention of acute and delayed chemotherapy-induced nausea and vomiting in malignant glioma patients receiving multidose irinotecan in combination with bevacizumab.

Články môžu prekladať iba registrovaní používatelia

Prihlásiť Registrácia

OBJECTIVE Given that the prognosis of recurrent malignant glioma (MG) remains poor, improving quality of life (QoL) through symptom management is important. Meta-analyses establishing antiemetic guidelines have demonstrated the superiority of palonosetron (PAL) over older 5-hydroxytryptamine

Randomized open-label phase II trial of 5-day aprepitant plus ondansetron compared to ondansetron alone in the prevention of chemotherapy-induced nausea-vomiting (CINV) in glioma patients receiving adjuvant temozolomide.

Články môžu prekladať iba registrovaní používatelia

Prihlásiť Registrácia

CINV remains a distressing side effect experienced by glioma patients receiving multi-day temozolomide therapy, in spite of guideline-based antiemetic therapy with selective serotonin-receptor-antagonists. Antiemetic research with aprepitant has routinely excluded glioma patients. In

Letter Referencing "Randomized Open-Label Phase II Trial of 5-day Aprepitant Plus Ondansetron Compared to Ondansetron Alone in the Prevention of Chemotherapy-Induced Nausea-Vomiting in Glioma Patients Receiving Adjuvant Temozolomide"

Články môžu prekladať iba registrovaní používatelia

Prihlásiť Registrácia

Response to the letter to the Editor concerning manuscript entitled, "Randomized open-label phase II trial of 5-day aprepitant plus ondansetron compared to ondansetron alone in the prevention of chemotherapy-induced nausea-vomiting (CINV) in glioma patients receiving adjuvant temozolomide"

Články môžu prekladať iba registrovaní používatelia

Prihlásiť Registrácia

Cross-Sectional Study of Temozolomide-Induced Chemotherapy-Induced Nausea and Vomiting in Patients with Glioma.

Články môžu prekladať iba registrovaní používatelia

Prihlásiť Registrácia

Optic nerve glioma and cerebellar astrocytoma in a patient with von Recklinghausen's neurofibromatosis.

Články môžu prekladať iba registrovaní používatelia

Prihlásiť Registrácia

A 2 and a half year-old boy with neurofibromatosis developed unilateral proptosis, decreased visual acuity, and optic disk edema. After the discovery and removal of an optic nerve glioma, the patient had ten years of excellent health until he began having headaches, nausea, and vomiting. He had

Deficits in Japanese word spelling as an initial language symptom of malignant glioma in the left hemisphere.

Články môžu prekladať iba registrovaní používatelia

Prihlásiť Registrácia

BACKGROUND A good performance status at diagnosis is a prognostic factor in patients with malignant glioma whose median survival is 24 months. As early diagnosis may improve their poor prognosis, we looked for currently unknown initial symptoms among patients in good performance status. METHODS We

Intraarterial infusion of carboplatin in the treatment of malignant gliomas: a phase II study.

Články môžu prekladať iba registrovaní používatelia

Prihlásiť Registrácia

Twenty-three previously treated patients with malignant gliomas were included in this phase II study of carboplatin (400 mg/m2) given as an intraarterial infusion every 4 weeks. Five patients (26% of 19 evaluable) achieved a partial response for 3 to 10 months and 5 patients presented a

Eight-drugs-in-one-day chemotherapy in postirradiated adult patients with malignant gliomas.

Články môžu prekladať iba registrovaní používatelia

Prihlásiť Registrácia

Fifteen patients, 12 with glioblastoma multiforme and 3 with anaplastic astrocytoma, were treated with "eight-drugs-in-one-day" chemotherapy [methylprednisolone 300 mg/m2, vincristine 1.5 mg/m2 (maximum of 2 mg/cycle), CCNU 75 mg/m2, procarbazine 75 mg/m2, hydroxyurea 3,000 mg/m2, cisplatin 90

Temozolomide in pediatric low-grade glioma.

Články môžu prekladať iba registrovaní používatelia

Prihlásiť Registrácia

BACKGROUND We describe a retrospective series of children with low-grade glioma who received temozolomide. METHODS Eligible patients had had a diagnosis of low-grade glioma with or without histological confirmation. Temozolomide was administered at a dose of 200 mg/m(2) daily for 5 days, in a 4-week

Phase I and pharmacokinetic study of preirradiation chemotherapy with BCNU, cisplatin, etoposide, and accelerated radiation therapy in patients with high-grade glioma.

Články môžu prekladať iba registrovaní používatelia

Prihlásiť Registrácia

OBJECTIVE We conducted a Phase I study of bischloroethylnitrosourea (BCNU), cisplatin, and oral etoposide administered prior to and during accelerated hyperfractionated radiation therapy in newly diagnosed high-grade glioma. Pharmacokinetic studies of oral etoposide were also done. METHODS Patients

A phase II study of nimustine hydrochloride, cisplatin, and etoposide combination chemotherapy for supratentorial malignant gliomas.

Články môžu prekladať iba registrovaní používatelia

Prihlásiť Registrácia

Twenty-eight patients who were previously treated by aggressive surgery and radiation and were diagnosed with supratentorial malignant gliomas received a combination of nimustine hydrochloride; 1-(4-amino-2-methyl-5-pyrimidinyl) methyl-3-(2-chloroethyl)-3-nitrosourea hydrochloride (ACNU), cisplatin

Toxicity profile of temozolomide in the treatment of 300 malignant glioma patients in Korea.

Články môžu prekladať iba registrovaní používatelia

Prihlásiť Registrácia

This study evaluated the toxicity profiles of temozolomide in the treatment of malignant glioma as either concurrent or adjuvant chemotherapy. We retrospectively reviewed the medical records of 300 malignant glioma patients treated with temozolomide in two medical institutions in Korea between 2004

A Phase I study of concurrent RMP-7 and carboplatin with radiation therapy for children with newly diagnosed brainstem gliomas.

Články môžu prekladať iba registrovaní používatelia

Prihlásiť Registrácia

BACKGROUND Ninety percent of children with diffuse, intrinsic brainstem tumors will die within 18 months of diagnosis. Radiotherapy is of transient benefit to these children, and a potential way to improve its efficacy is to add radiosensitizers. Carboplatin is antineoplastic and radiosensitizing;

A phase II study of carboplatin and chronic high-dose tamoxifen in patients with recurrent malignant glioma.

Články môžu prekladať iba registrovaní používatelia

Prihlásiť Registrácia

OBJECTIVE To determine the response rate, time to disease progression, survival, and toxicity of intravenous carboplatin and chronic oral high-dose tamoxifen in patients with recurrent malignant gliomas. METHODS Patients with histological confirmation of recurrent malignant gliomas were eligible for

Predchádzajúce
1
2
3
4
5
6
...
14
15
Ďalšie

Pripojte sa k našej
facebookovej stránke

Herbal & Natural Medicine

Najkompletnejšia databáza liečivých bylín podporovaná vedou

Pracuje v 55 jazykoch
Bylinné lieky podporené vedou
Rozpoznávanie bylín podľa obrázka
Interaktívna GPS mapa - označte byliny na mieste (už čoskoro)
Prečítajte si vedecké publikácie týkajúce sa vášho hľadania
Vyhľadajte liečivé byliny podľa ich účinkov
Usporiadajte svoje záujmy a držte krok s novinkami, klinickými skúškami a patentmi

Zadajte príznak alebo chorobu a prečítajte si o bylinách, ktoré by vám mohli pomôcť, napíšte bylinu a pozrite sa na choroby a príznaky, proti ktorým sa používa.
* Všetky informácie sú založené na publikovanom vedeckom výskume